# Achieve Life Sciences, Inc.

**ACHV**

Nasdaq; healthcare; SIC 2835, In Vitro & In Vivo Diagnostic Substances; CIK 0000949858

# None

### No letter

4 of 14 inputs computable; 7 are required, with a score in every sleeve

| Scoreboard | |
|---|---|
| **Reliability** | 0.83 AUC<br>filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025 |
| **Peer failure rate** | 1.07% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $12.5M to $120M assets<br>total assets $41.8M |
| **Standard universe** | outside<br>revenue above $1M and assets above $10M |
| **Warnings** | thin data, degenerate inputs<br>not computable: dilution, fortress balance sheet |
| **Inputs computable** | 4 of 14 |
| **Graded from** | filings received through Apr 30, 2026<br>180 days before the rescan; latest periodic filing 10-Q received Aug 11, 2026 |
| **Last close** | $6.54<br>2026-10-26; market equity $673.5M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 24, 2026*

We are a late-stage clinical specialty pharmaceutical company with the sole mission to address the global nicotine dependence epidemic through the development and commercialization of cytisinicline. There are an estimated 29 million adults in the United States alone who smoke combustible cigarettes and an estimated 17 million adults in the United States who utilize e-cigarettes. Tobacco use is currently the leading cause of preventable death and is responsible for more than eight million deaths worldwide and nearly half a million deaths in the United States annually.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 33.7** | | | | | | |
| Gross profitability | not computable | 32.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Return on invested capital | not computable | 9.3% | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| *one or more required annual facts are missing* | | | | | |
| Accruals ratio | (12.9%) | (6.6%) | 33.7 | 805 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | |
| *five annual gross margins are required; found 0* | | | | | |
| **Solvency, sleeve percentile 56.1** | | | | | |
| Twelve-month failure probability | 0.20% | 0.07% | 70.3 | 247 | 2026-06-30 |
| Altman Z double-prime | not computable | (0.33) | | | |
| *one or more required annual facts are missing* | | | | | |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *one or more required annual facts are missing* | | | | | |
| Interest coverage | not computable | (4.51x) | | | |
| *one or more required annual facts are missing* | | | | | |
| Current ratio | 4.39x | 2.94x | 41.9 | 832 | 2025-12-31 |
| **Growth and financing, sleeve percentile 29.9** | | | | | |
| Revenue growth, three-year compound | not computable | 10.1% | | | |
| *four annual observations are required; found 2* | | | | | |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | |
| *four consecutive annual FCF observations are required; found 11* | | | | | |
| Reinvestment rate | not computable | 37.1% | | | |
| *one or more required annual facts are missing* | | | | | |
| Asset growth, three years | 11.7% | 2.1% | 29.9 | 697 | 2025-12-31 |
| Net share issuance, one year | not computable | 2.5% | | | |
| *prior share count is 27 days earlier* | | | | | |

## Warnings

*2 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Thin data | 4 of 14 grade factors are computable; minimum is 7 |
| Degenerate inputs | latest revenue or assets are at or below the $100,000 validity floor |

## What the price implies

*at the 2026-10-26 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 152.1% | 7.7% | 93 |
| Distance from 52-week high | (23.3%) | (31.2%) | 60 |
| EBIT to enterprise value | not computable | (1.5%) | |
| Free cash flow yield | (7.4%) | (1.0%) | 37 |
| Book value to price | (0.02) | 0.28 | 10 |
| Sales to price | 0.00 | 0.30 | 0 |
| Composite equity issuance, five years | 281.7% | 20.5% | 95 |
| Relative strength against the sector, log excess return | 0.71 | (0.14) | 93 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | pass |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | fail |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $48.0M |
| Operating cash flow, four quarters | -$47.0M |
| Months of runway | 12.2 |
| Days since last periodic filing | 77 (10-Q received Aug 11, 2026) |
| Median daily dollar volume, 63 sessions | $8.9M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | net income | us-gaap:NetIncomeLoss | -$54.6M | 2025-12-31 | 2026-03-24 | 10-K | 26-120690 |
| 2 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$49.5M | 2025-12-31 | 2026-03-24 | 10-K | 26-120690 |
| 3 | assets | us-gaap:Assets | $41.8M | 2025-12-31 | 2026-03-24 | 10-K | 26-120690 |
| 4 | assets | us-gaap:Assets | $38.6M | 2024-12-31 | 2026-03-24 | 10-K | 26-120690 |
| 5 | current assets | us-gaap:AssetsCurrent | $39.9M | 2025-12-31 | 2026-03-24 | 10-K | 26-120690 |
| 6 | current liabilities | us-gaap:LiabilitiesCurrent | $9.1M | 2025-12-31 | 2026-03-24 | 10-K | 26-120690 |
| 7 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $0 | 2019-12-31 | 2020-03-13 | 10-K | 20-010642 |
| 8 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $0 | 2018-12-31 | 2019-03-14 | 10-K | 19-007838 |
| 9 | assets | us-gaap:Assets | $19.4M | 2023-12-31 | 2025-03-11 | 10-K | 25-036831 |
| 10 | assets | us-gaap:Assets | $30.0M | 2022-12-31 | 2024-03-28 | 10-K | 24-038049 |
| 11 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 102,659,057 | 2026-04-20 | 2026-04-30 | 10-K/A | 26-197402 |
| 12 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 53,239,988 | 2026-03-24 | 2026-03-24 | 10-K | 26-120690 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.